An adjustable predictive score of graft survival in kidney transplant patients and the levels of risk linked to de novo donor-specific anti-HLA antibodies

被引:15
|
作者
Premaud, Aurelie [1 ,2 ]
Filloux, Matthieu [3 ,4 ]
Gatault, Philippe [5 ]
Thierry, Antoine [6 ]
Buchler, Matthias [5 ]
Munteanu, Eliza [7 ]
Marquet, Pierre [1 ,2 ,8 ]
Essig, Marie [1 ,2 ,7 ]
Rousseau, Annick [1 ,2 ]
机构
[1] INSERM, U850, Limoges, France
[2] Univ Limoges, UMR S850, Limoges, France
[3] CHU Limoges, Serv Immunol & Immunogenet, Limoges, France
[4] CNRS, CRIBL, UMR 7276, Limoges, France
[5] CHU Tours, Serv Nephrol & Immunol Clin, Tours, France
[6] CHU Poitiers, Serv Nephrol Hemodialyse Transplantat Renal, Poitiers, France
[7] CHU Limoges, Serv Nephrol, Dialyse Transplantat, Limoges, France
[8] CHU Limoges, Serv Pharmacol Toxicol & Pharmacovigilance, Limoges, France
来源
PLOS ONE | 2017年 / 12卷 / 07期
关键词
RENAL-TRANSPLANTATION; SERUM CREATININE; ALLOGRAFT LOSS; FAILURE; REJECTION; OUTCOMES; FORESTS; SYSTEM; COHORT; TIME;
D O I
10.1371/journal.pone.0180236
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Most predictive models and scores of graft survival in renal transplantation include factors known before transplant or at the end of the first year. They cannot be updated thereafter, even in patients developing donor-specific anti-HLA antibodies and acute rejection. We developed a conditional and adjustable score for prediction of graft failure (AdGFS) up to 10 years post-transplantation in 664 kidney transplant patients. AdGFS was externally validated and calibrated in 896 kidney transplant patients. The final model included five baseline factors (pretransplant non donor-specific anti-HLA antibodies, donor age, serum creatinine measured at 1 year, longitudinal serum creatinine clusters during the first year, proteinuria measured at 1 year), and two predictors updated over time (de novo donor-specific anti-HLA antibodies and first acute rejection). AdGFS was able to stratify patients into four riskgroups, at different post-transplantation times. It showed good discrimination (time-dependent ROC curve at ten years: 0.83 (CI95% 0.76-0.89).
引用
收藏
页数:16
相关论文
共 50 条
  • [41] Impact of Anti-HLA De Novo Donor Specific Antibody on Graft Outcomes in Pancreas Transplantation: A Meta-Analysis
    Khan, Sualeh Muslim
    Sumbal, Ramish
    Schenk, Austin D.
    TRANSPLANTATION PROCEEDINGS, 2021, 53 (10) : 3022 - 3029
  • [42] Occurrence of De novo Donor-Specific Antibodies After COVID-19 in Kidney Transplant Recipients Is Low Despite Immunosuppression Modulation
    Masset, Christophe
    Gautier-Vargas, Gabriela
    Cantarovich, Diego
    Ville, Simon
    Dantal, Jacques
    Delbos, Florent
    Walencik, Alexandre
    Kerleau, Clarisse
    Hourmant, Maryvonne
    Garandeau, Claire
    Meurette, Aurelie
    Giral, Magali
    Benotmane, Ilies
    Caillard, Sophie
    Blancho, Gilles
    KIDNEY INTERNATIONAL REPORTS, 2022, 7 (07): : 983 - 992
  • [43] HLA B eplet mismatches in the context of delayed graft function and low tacrolimus trough levels are risk factors influencing the generation of de novo donor-specific antibodies and acute rejection in the early stage after kidney transplantation
    Gao, Shan
    Gong, Huilin
    Li, Meihe
    Lan, Ping
    Zhang, Minyue
    Kuang, Peidan
    Zhang, Ying
    Hu, Xiaojun
    Ding, Chenguang
    Li, Yang
    Ding, Xiaoming
    Xue, Wujun
    Zheng, Jin
    TRANSPLANT IMMUNOLOGY, 2023, 81
  • [44] Results of early treatment for de novo donor-specific antibodies in pediatric kidney transplant recipients in a cross-sectional and longitudinal cohort
    Charnaya, Olga
    Tuchman, Shamir
    Moudgil, Asha
    PEDIATRIC TRANSPLANTATION, 2018, 22 (02)
  • [45] The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients
    O'Leary, Jacqueline G.
    Samaniego, Millie
    Crespo Barrio, Marta
    Potena, Luciano
    Zeevi, Adriana
    Djamali, Arjang
    Cozzi, Emanuele
    TRANSPLANTATION, 2016, 100 (01) : 39 - 53
  • [46] Association between blood transfusion after kidney transplantation and risk for the development of de novo HLA donor-specific antibodies and poor clinical outcomes: A single-center retrospective study
    Kang, Zhong-Yu
    Liu, Chun
    Liu, Wei
    Li, Daihong
    TRANSPLANT IMMUNOLOGY, 2023, 81
  • [47] Renal transplant outcomes and de novo donor-specific anti-human leukocyte antigen antibodies: a systematic review
    Sharma, Ankit
    Lewis, Joshua R.
    Lim, Wai H.
    Palmer, Suetonia
    Strippoli, Giovanni
    Chapman, Jeremy R.
    Alexander, Stephen I.
    Craig, Jonathan C.
    Wong, Germaine
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33 (08) : 1472 - 1480
  • [48] Influence of pretransplant class I and II non-donor-specific anti-HLA immunization on immunologic outcome and graft survival in kidney transplant recipients
    Staeck, Anja
    Khadzhynov, Dmytro
    Kleinsteuber, Anna
    Lehner, Lukas
    Duerr, Michael
    Budde, Klemens
    Lachmann, Nils
    Halleck, Fabian
    Staeck, Oliver
    TRANSPLANT IMMUNOLOGY, 2020, 63
  • [49] Acquisition of C3d-Binding Activity by De Novo Donor-Specific HLA Antibodies Correlates With Graft Loss in Nonsensitized Pediatric Kidney Recipients
    Comoli, P.
    Cioni, M.
    Tagliamacco, A.
    Quartuccio, G.
    Innocente, A.
    Fontana, I.
    Trivelli, A.
    Magnasco, A.
    Nocco, A.
    Klersy, C.
    Rubert, L.
    Ramondetta, M.
    Zecca, M.
    Garibotto, G.
    Ghiggeri, G. M.
    Cardillo, M.
    Nocera, A.
    Ginevri, F.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2016, 16 (07) : 2106 - 2116
  • [50] Comparison of high-dose IVIG and rituximab versus rituximab as a preemptive therapy for de novo donor-specific antibodies in kidney transplant patients
    Kim, Hyung Woo
    Lee, Juhan
    Heo, Seok-Jae
    Kim, Beom Seok
    Huh, Kyu Ha
    Yang, Jaeseok
    SCIENTIFIC REPORTS, 2023, 13 (01)